Clinical Trial Update: AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation [Phase 4]

View source ↗

Summary

Phase 4 trial update comparing Envarsus XR (extended-release tacrolimus) with standard twice-daily tacrolimus in kidney transplant recipients; current status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Renal Allograft Rejection

Drugs mentioned

• Envarsus XR (Tacrolimus)
• Prograf (Tacrolimus)

Snippet

Sponsor: University Hospital Birmingham NHS Foundation Trust | Conditions: Kidney Transplant Failure and Rejection | Phase 4 | Status: UNKNOWN